Skip to main content

Table 2 Univariate analysis of prognostic factors for 272 patients with stage III NPC

From: Efficacy of concurrent chemoradiotherapy in subgroups of stage III nasopharyngeal carcinoma: an analysis based on 10-year follow-up

Variables

LRFS

DMFS

DFS

OS

HR (95% CI)

P

HR (95% CI)

P

HR (95% CI)

P

HR (95% CI)

P

Sex (male vs. female)

0.978 (0.400–2.392)

0.961

0.922 (0.462–1.840)

0.818

0.874 (0.499–1.530)

0.637

0.779 (0.407–1.491)

0.451

Age (≤ 43 vs. > 43, year)

1.254 (0.612–2.570)

0.537

1.224 (0.706–2.122)

0.471

1.450 (0.936–2.247)

0.096

2.087 (1.252–3.480)

0.005

Smoking (yes vs. no)

0.662 (0.323–1.357)

0.260

0.618 (0.356–1.073)

0.087

0.617 (0.399–0.953)

0.030

0.472 (0.286–0.781)

0.003

Alcohol (yes vs. no)

0.749 (0.321–1.746)

0.503

0.748 (0.392–1.430)

0.380

0.707 (0.427–1.170)

0.177

0.594 (0.341–1.035)

0.066

T classification (T1-2 vs. T3)

1.486 (0.371–2.014)

0.735

1.580 (0.445–1.623)

0.622

1.268 (0.520–1.451)

0.590

1.069 (0.581–1.966)

0.830

 N classification (N0-1 vs. N2)

1.890 (0.923–3.873)

0.082

1.672 (0.965–2.895)

0.067

1.670 (1.083–2.575)

0.020

1.506 (0.922–2.459)

0.102

CCT (yes vs. no)

1.721 (0.828–3.575)

0.146

1.485 (0.842–2.620)

0.172

1.721 (1.106–2.678)

0.016

1.976 (1.205–3.239)

0.007

EBV DNA (< 2000 vs. ≥ 2000)

1.747 (0.750–4.071)

0.196

1.398 (0.756–2.585)

0.286

1.084 (0.684–1.718)

0.732

1.081 (0.649–1.802)

0.764

  1. NPC, nasopharyngeal carcinoma; HR, hazard ratio; CI, confidence interval; LRFS, locoregional-free survival; DMFS, distant metastasis-free survival; DFS, disease-free survival; OS, overall survival; CCT, concurrent chemotherapy; EBV, Epstein–Barr virus